China's Innovative Cellular Therapeutics Reports 90% Remission Rate in CAR-T Trial

Innovative Cellular Therapeutics, a China cell therapy company, announced that its CAR-T product achieved a 90% remission rate in leukemia patients, each of whom had relapsed/refractory disease. The results, which came from a small initial trial of ten patients, were reported at the 2016 Hematogenic Immunity Summit held in Hangzhou last month. The trial was conducted jointly by the First Affiliated Hospital of Zhejiang University and ICT. According to Professor Huang He of Zhejiang Hospital, the results were best-in-class for global CAR-T trials. More details.... Share this with colleagues: // //